Obalon Therapeutics, Inc. announces that William Plovanic, the Company's President and CEO has announced his resignation in order to accept another position. Andy Rasdal, Executive Chairman and former CEO from June 2008 through January 2019, will assume the position of CEO upon Mr. Plovanic's departure. To assist the Company in the transition, Mr. Plovanic has agreed to remain as President and CEO through completion and filing of Obalon's Form 10-Q for the quarter ended March 31, 2020 (the “Quarterly Report”).

During the transition period, Mr. Plovanic will also begin to perform duties related to his new role with another organization. Mr. Plovanic will continue to serve as a director of Obalon after his transition.